Tracers / [225Ac]Ac-DOTAGA-FAP-2286-ALB

[225Ac]Ac-DOTAGA-FAP-2286-ALB

Also written as [Ac-225]Ac-DOTAGA-FAP-2286-ALB

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet Fibroblast activation / tumour stroma

What it is

Compound class: FAP-2286-based DOTAGA peptide with albumin binder (FAP-targeting radioligand)
Target / mechanism: Fibroblast activation protein (FAP) PMID 40236533
Clinical application: Cancer (FAP-expressing tumors) - diagnosis and therapy PMID 40236533
Theranostic pair: <a href="/tracers/in111-dotagafap2286alb/">in111-dotagafap2286alb</a>

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	DOTAGA-FAP-2286-ALB	40236533 2025 ACS Med Chem Lett

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTAGA-FAP-2286-ALB, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40236533. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40236533: 'We designed DOTAGA-FAP-2286 and DOTAGA-FAP-2286-ALB'.